Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Shih-Hsien Hsu
 -- 1172 2023-08-15 03:00:43 |
2 format correct
Catherine Yang
 Meta information modification 1172 2023-08-15 03:04:25 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Lin, P.; Hsu, W.; Lee, P.; Chiou, S.; Hsu, S. Pathogenesis of Iron Overload and Hepatocellular Carcinoma. Encyclopedia. Available online: https://encyclopedia.pub/entry/48060 (accessed on 30 June 2024).
Lin P, Hsu W, Lee P, Chiou S, Hsu S. Pathogenesis of Iron Overload and Hepatocellular Carcinoma. Encyclopedia. Available at: https://encyclopedia.pub/entry/48060. Accessed June 30, 2024.
Lin, Pei-Chin, Wan-Yi Hsu, Po-Yi Lee, Shyh-Shin Chiou, Shih-Hsien Hsu. "Pathogenesis of Iron Overload and Hepatocellular Carcinoma" Encyclopedia, https://encyclopedia.pub/entry/48060 (accessed June 30, 2024).
Lin, P., Hsu, W., Lee, P., Chiou, S., & Hsu, S. (2023, August 15). Pathogenesis of Iron Overload and Hepatocellular Carcinoma. In Encyclopedia. https://encyclopedia.pub/entry/48060
Lin, Pei-Chin, et al. "Pathogenesis of Iron Overload and Hepatocellular Carcinoma." Encyclopedia. Web. 15 August, 2023.
Pathogenesis of Iron Overload and Hepatocellular Carcinoma
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms241612654

Hepatocellular carcinoma (HCC) is one of the most common malignancies in both transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). The mechanisms of iron-overloading-associated HCC development include the increased reactive oxygen species (ROS), inflammation cytokines, dysregulated hepcidin, and ferroportin metabolism.

thalassemia iron transfusion-dependent thalassemia Hepatocellular carcinoma (HCC)

1. Iron and Inflammation

When intrahepatic iron overflows, hepatocytes are also stimulated to differentiate into a proinflammatory state through excessive intracellular ferritin by enhancing the NF-κB expression pathway [1]. Prolonged activation of hepatocytes means they can differentiate into myofibroblasts and lead to neovascularization and extracellular matrix formation. Excessive iron molecules are not only deposited in but also injure hepatocytes. They also affect immune system function. Liver, as the largest reticuloendothelial system in the body, contains the largest population of macrophages (Kupffer cells). Macrophages, as scavengers in the body, phagocytize not only external harmful agents, such as bacteria, but also old dysfunctional cells, such as senescent RBCs and destroyed hepatocytes. Thus, they are prone to contain excessive amounts of iron, especially in patients with thalassemia. Excessive amounts of iron induce the macrophage to secrete proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-12 (IL-12) [2]. Together, with the proinflammatory status of hepatocytes, complicated chronic inflammatory interaction ensues. Hepatic stellate cells, endothelial cells, and lymphocytes inside the liver all participate, and cirrhosis begins [3]. Cirrhosis provides an oncogenic environment for HCC formation [4][5][6]. A study of human liver tissue revealed that hepatocytes were polarized to myofibroblasts when the liver iron concentration (LIC) was >60 μmol/g. Cirrhosis ensues when the LIC is >250 μmol/g [7]. Fibrosis develops when the LIC is >400 μmol/g [8].

2. Iron and Reactive Oxygen Species (ROS)

When intracellular iron is excessive, these iron molecules participate in the Fenton reaction (Figure 1) and cause the accumulation of ROS [9]. Healthy cells can detoxify ROS through nonenzymatic and enzymatic antioxidants, such as glutathione, flavonoids, superoxide reductase, catalase, and glutathione peroxidase. If ROS formation exceeds the detoxifying ability of cells, excess ROS can cause genomic instability and reprogram cell metabolism toward carcinogenesis [10]. ROS induce hypoxia-inducible factor-1α expression and related angiogenic gene expression and thus promote angiogenesis [11]. ROS can also promote ERK/NF-kB pathway activation and facilitate tumor cell growth, migration, and deposition of extracellular matrix [12]. To summarize, ROS enhance tumor cell proliferation and survival.
Figure 1. Mechanism of ROS accumulation caused by the Fenton reaction. The reaction of peroxides with Fe2+ to yield soluble hydroxyl (HO•) or lipid alkoxy (RO•) radicals is referred to as the Fenton reaction.
Other than iron, HBV/HCV infection and NASH/NAFLD status provide many oxidative stresses to hepatocytes as well. In NAFLD, elevated mitochondrial fatty acid oxidation and impaired respiratory chain activity make ROS accumulate [13]. It was found that the HBV structural protein-HBx damaged the mitochondrial membrane potential by interacting with the outer membrane and affecting the respiratory complex; ROS production then increased [14]. With chronic HCV infection status, patients usually have a higher liver iron content and thus high ROS production [15]. Thus, in thalassemia patients, co-existence of hepatic viral infection and/or NAFLD with iron overload makes them vulnerable to hepatocarcinogenesis.

3. Hepcidin and Ferriportin

Hepcidin is a polypeptide hormone, isolated from plasma and urine samples with antimicrobial activities by two research groups in 2000 [16][17]. They showed that hepcidin was mainly produced by the liver, followed by the heart, brain, and lung [16]. Almost at the same time, Pigeon et al. tested the hepatic gene expressions in iron-overload mouse models and showed that hepcidin (HEPC), the gene encoding hepcidin, was overexpressed in iron overload hepatic cells. In the report, they also mapped the gene to the human chromosome 19 close to the upstream stimulatory factor-2 (USF2) gene [18]. Lipopolysaccharide, a main component of pathogenic molecules, acts on macrophages, including hepatic Kupffer cells, to induce interleukin-6 (IL-6) production, which in turn induces the overexpression of hepcidin mRNA in hepatocytes [19][20]. In summary, iron overloading, infection, and inflammation can induce hepatocyte hepcidin secretion, which leads to hypoferremia and the anemia of chronic inflammation. Anemia and hypoxia suppress hepcidin expression and result in tissue iron overload. Hepcidin regulates the absorption of dietary iron from the intestine, the release of recycled hemoglobin iron by macrophages, and the movement of stored iron from hepatocytes by blocking the iron transport in the intestinal epithelium, the placenta, and the macrophage [19]. Ferriportin, the only ion exporter in human cells, plays a critical role in hepcidin-regulated iron metabolism, where ferriportin–hepcidin binding leads to the internalization and degradation of ferriportin, and due to the decreased amounts of ferripotin, iron is trapped in hepatocytes, macrophages, and absorptive enterocytes. In consequence, cytoplasmic iron accumulates and reduces the cell uptake of iron. After plasma iron becomes depleted, mainly through hemoglobin synthesis by red cell precursors in the bone marrow, the hepcidin expression is suppressed and restores the iron hemostasis system [21].
As a key regulator of iron metabolism, hepcidin levels are influenced in the pathogenesis of anemia. Inefficient erythropoietic anemias, such as thalassemia, whose clinical manifestation is iron overload anemia, iron deficiency anemia, and congenital erythropoiesis, often have low or abnormal hepcidin relative to the anemia [22]. Kijima et al. examined hepcidin expression in cancerous and noncancerous liver tissues from 40 HCC patients and found that hepcidin mRNA expression was significantly suppressed in cancerous tissues compared to noncancerous liver tissues. It is noncancerous in HCC patients, regardless of the disease state such as tumor differentiation or the time to relapse. There was no significant difference in the mRNA expression of ferripotin and transferrin receptor 2 (TfR2) between cancerous and noncancer tissues [23]. On the other hand, Tan et al. found that hepcidin, TfR2, transferrin (Tf), ceruloplasmin (Cp), and iron regulatory protein 1 (IRP1), isolated in 24 HCC patients with chronic HBV infection, were downregulated compared to the adjacent tumor-free liver tissue and normal liver controls [24]. Similarly, Tseng et al. found that hepcidin, ceruloplasmin, transferrin, and transferrin-phosphorus receptor 2 were downregulated, transferrin receptor 1 was upregulated, and the hepcidin levels consistently correlated with hepatic iron stores in 50 HCC patients [25]. Kessler et al. showed that in cirrhotic tissues, hepcidin expression was lower compared to healthy liver samples in an HBV-related cohort as well as in HCV-infected patients, hepcidin expression was even lower in the HCC samples, and in their mouse models, they showed that hepcidin expression was decreased in early hepatocarcinogenesis as well as in a later stage of murine tumorigenesis [26]. Hepcidin also ameliorates liver fibrosis by inhibiting hepatic stellate cells (HSCs)’ activation, which facilitates liver fibrosis via the degradation of ferroportin in HSCs, increasing Akt phosphorylation and finally prohibiting TGFb1-inducible Smad3 phosphorylation [27].
The underlying mechanisms of suppressed hepcidin in HCC included the suppression of HAMP, TfR2, HJV, ALK2, and/or circular RNA circ_0004913, upregulations of matriptase-2 and/or GDF15, and the inactivation of RUNX3 and/or mutations in TP53 [28]. Hepcidin-induced ferriportin dysregulation has been reported to be associated with an increased risk of cancer, including HCC. FPN overexpression has been reported to be associated with a significant reduction in clonogenic ability, tumor regression, and liver metastasis in breast cancer cells [29][30]. The effects of hepcidin downregulation involve increased cancer proliferation via activation of the CDK1/STAT3 pathway and JAK/STAT pathway in a dependent manner [28][31].

References

  1. Ruddell, R.G.; Hoang-Le, D.; Barwood, J.M.; Rutherford, P.S.; Piva, T.J.; Watters, D.J.; Santambrogio, P.; Arosio, P.; Ramm, G.A. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB–regulated signaling in rat hepatic stellate cells. Hepatology 2009, 49, 887–900.
  2. Sindrilaru, A.; Peters, T.; Wieschalka, S.; Baican, C.; Baican, A.; Peter, H.; Hainzl, A.; Schatz, S.; Qi, Y.; Schlecht, A.; et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Investig. 2011, 121, 985–997.
  3. Ringelhan, M.; Pfister, D.; O’Connor, T.; Pikarsky, E.; Heikenwalder, M. The immunology of hepatocellular carcinoma. Nat. Immunol. 2018, 19, 222–232.
  4. Hoshida, Y.; Villanueva, A.; Sangiovanni, A.; Sole, M.; Hur, C.; Andersson, K.L.; Chung, R.T.; Gould, J.; Kojima, K.; Gupta, S.; et al. Prognostic gene expression signature for patients with hepatitis C–related early-stage cirrhosis. Gastroenterology 2013, 144, 1024–1030.
  5. Budhu, A.; Forgues, M.; Ye, Q.-H.; Jia, H.-L.; He, P.; Zanetti, K.A.; Kammula, U.S.; Chen, Y.; Qin, L.-X.; Tang, Z.-Y.; et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10, 99–111.
  6. Moeini, A.; Torrecilla, S.; Tovar, V.; Montironi, C.; Andreu-Oller, C.; Peix, J.; Higuera, M.; Pfister, D.; Ramadori, P.; Pinyol, R.; et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology 2019, 157, 1383–1397.e11.
  7. Adams, P.C. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am. J. Gastroenterol. 2001, 96, 567–569.
  8. Angelucci, E.; Muretto, P.; Nicolucci, A.; Baronciani, D.; Erer, B.; Gaziev, J.; Ripalti, M.; Sodani, P.; Tomassoni, S.; Visani, G.; et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood J. Am. Soc. Hematol. 2002, 100, 17–21.
  9. Dixon, S.J.; Stockwell, B.R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 2014, 10, 9–17.
  10. Moloney, J.N.; Cotter, T.G. Seminars in Cell & Developmental Biology; Elsevier: Amsterdam, The Netherlands, 2018; pp. 50–64.
  11. Choi, J.-E.; Kim, J.-H.; Song, N.-Y.; Suh, J.; Kim, D.-H.; Kim, S.-J.; Na, H.-K.; Nadas, J.; Dong, Z.; Cha, Y.-N.; et al. 15-Deoxy-Δ12, 14-prostaglandin J2 stabilizes hypoxia inducible factor-1α through induction of heme oxygenase-1 and direct modification ofprolyl-4-hydroxylase 2. Free Radic. Res. 2016, 50, 1140–1152.
  12. Cao, L.; Liu, J.; Zhang, L.; Xiao, X.; Li, W. Curcumin inhibits H2O2-induced invasion and migration of human pancreatic cancer via suppression of the ERK/NF-κB pathway. Oncol. Rep. 2016, 36, 2245–2251.
  13. Begriche, K.; Massart, J.; Robin, M.A.; Bonnet, F.; Fromenty, B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013, 58, 1497–1507.
  14. Lee, H.R.; Cho, Y.; Lee, G.; You, D.; Yoo, Y.; Kim, Y. A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization. J. Viral Hepat. 2018, 25, 412–420.
  15. Lambrecht, R.W.; Sterling, R.K.; Naishadham, D.; Stoddard, A.M.; Rogers, T.; Morishima, C.; Morgan, T.R.; Bonkovsky, H.L.; Group, H.-C.T. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011, 140, 1490–1500.e3.
  16. Krause, A.; Neitz, S.; Mägert, H.J.; Schulz, A.; Forssmann, W.G.; Schulz-Knappe, P.; Adermann, K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000, 480, 147–150.
  17. Park, C.H.; Valore, E.V.; Waring, A.J.; Ganz, T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276, 7806–7810.
  18. Pigeon, C.; Ilyin, G.; Courselaud, B.; Leroyer, P.; Turlin, B.; Brissot, P.; Loréal, O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 2001, 276, 7811–7819.
  19. Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102, 783–788.
  20. Nemeth, E.; Valore, E.V.; Territo, M.; Schiller, G.; Lichtenstein, A.; Ganz, T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101, 2461–2463.
  21. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090–2093.
  22. Pagani, A.; Nai, A.; Silvestri, L.; Camaschella, C. Hepcidin and anemia: A tight relationship. Front. Physiol. 2019, 10, 1294.
  23. Kijima, H.; Sawada, T.; Tomosugi, N.; Kubota, K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 2008, 8, 167.
  24. Tan, M.G.K.; Kumarasinghe, M.P.; Wang, S.M.; Ooi, L.L.P.; Aw, S.E.; Hui, K.M. Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp. Biol. Med. 2009, 234, 693–702.
  25. Tseng, H.H.; Chang, J.G.; Hwang, Y.H.; Yeh, K.T.; Chen, Y.L.; Yu, H.S. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J. Cancer Res. Clin. Oncol. 2009, 135, 1413–1420.
  26. Kessler, S.M.; Barghash, A.; Laggai, S.; Helms, V.; Kiemer, A.K. Hepatic hepcidin expression is decreased in cirrhosis and HCC. J. Hepatol. 2015, 62, 977–979.
  27. Han, C.Y.; Koo, J.H.; Kim, S.H.; Gardenghi, S.; Rivella, S.; Strnad, P.; Hwang, S.J.; Kim, S.G. Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt. Nat. Commun. 2016, 7, 13817.
  28. Joachim, J.H.; Mehta, K.J. Hepcidin in hepatocellular carcinoma. Br. J. Cancer 2022, 127, 185–192.
  29. Zhang, S.; Chen, Y.; Guo, W.; Yuan, L.; Zhang, D.; Xu, Y.; Nemeth, E.; Ganz, T.; Liu, S. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell. Signal. 2014, 26, 2539–2550.
  30. Guo, W.; Zhang, S.; Chen, Y.; Zhang, D.; Yuan, L.; Cong, H.; Liu, S. An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim. Biophys. Sin. 2015, 47, 703–715.
  31. Rah, B.; Farhat, N.M.; Hamad, M.; Muhammad, J.S. JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: Therapeutic implications. Clin. Exp. Med. 2023.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Gastroenterology & Hepatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Pei-Chin Lin
,
Wan-Yi Hsu
,
Po-Yi Lee
,
Shyh-Shin Chiou
,
Shih-Hsien Hsu
View Times: 504
Entry Collection: Gastrointestinal Disease
Revisions: 2 times (View History)
Update Date: 15 Aug 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback